Are there potential problems with generic substitution of antiepileptic drugs?: A review of issues
- 30 April 2006
- journal article
- review article
- Published by Elsevier BV in Seizure
- Vol. 15 (3), 165-176
- https://doi.org/10.1016/j.seizure.2005.12.010
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- BIO-AVAILABILITY AND DISSOLUTION OF THREE PHENYTOIN PREPARATIONS FOR CHILDRENDevelopmental Medicine and Child Neurology, 2008
- The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugsClinical Therapeutics, 2003
- Effects of Switching From Depakene to Generic Valproic Acid on Individuals With Mental RetardationMental Retardation, 1997
- Generic DrugsDrug Safety, 1996
- Bioavailability and dissolution of proprietary and generic formulations of phenytoin.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Comparison on Bioequivalence of Four Phenytoin Preparations in Patients with Multiple‐Dose TreatmentThe Journal of Clinical Pharmacology, 1992
- GENERIC VERSUS BRANDED CARBAMAZEPINEThe Lancet, 1987
- Generic Equivalents: Issues and ConcernsThe Journal of Clinical Pharmacology, 1986
- A comparative study of the bioavailability of five different phenytoin preparationsJournal of Pharmacy and Pharmacology, 1985
- Comparative Bioavailability of Phenytoin from Generic Formulations in the United KingdomEpilepsia, 1982